FDA recognises nicotine pouches’ life-saving potential as Europe heads in the opposite direction

The world’s most influential health regulator has recognised that nicotine pouches can dramatically reduce smokers’ risk of deadly disease – just as the European Union is considering new restrictions that could make these products less accessible.

The U.S. Food and Drug Administration (FDA) has authorised 20 ZYN nicotine pouch products to be marketed with the statement: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.”

The landmark decision follows years of scientific review covering toxicology, clinical evidence, consumer behaviour and population health impacts. The FDA concluded that allowing the claim would benefit public health by helping adult smokers make informed decisions.

Smoke Free Sweden says the decision should serve as a wake-up call for European policymakers, who are considering tighter restrictions and higher taxes on nicotine pouches as part of revisions to the EU’s tobacco legislation.

“The FDA has reached a simple conclusion after examining the evidence,” said Dr Delon Human, leader of Smoke Free Sweden. “Smokers who switch from cigarettes to authorised nicotine pouches reduce their risk of developing some of the world’s biggest smoking-related diseases.

“It is extraordinary that while the United States is recognising the public health value of these products, parts of Europe are moving towards making them harder to access and trapping millions of smokers with deadly cigarettes.”

The FDA’s decision marks the first time a nicotine pouch has been authorised to carry a modified-risk claim and reinforces the lesson from Sweden’s own experience. 

Sweden’s progressive approach to snus and nicotine pouches has driven it towards internationally recognised smoke-free status, with daily smoking falling below 5%. At the same time, it records the lowest rates of tobacco-related disease in Europe. 

Despite that evidence, the European Commission is considering measures that could impose stricter regulation and heavier taxation on nicotine pouches, while several Member States have already introduced or proposed severe restrictions.

“The European Union says it wants to create a smoke-free generation,” Dr Human said. “That goal becomes harder to achieve if policymakers make it more difficult for smokers to choose products that eliminate the smoke responsible for almost all smoking-related disease.

“The FDA has demonstrated what evidence-based regulation looks like. It assessed the science, weighed the risks and benefits and reached a conclusion based on public health rather than politics. Europe should be doing the same: following the science, not ignoring it.”